VistaGen Therapeutics, Inc. (VTGN) Social Stream



VistaGen Therapeutics, Inc. (VTGN): $2.74

-0.01 (-0.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VTGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 499

in industry

Featured Post From StockTwits About VTGN

$VTGN May I as the bio experts in this Board to opine on likelihood of Phase III success? It seems like Phase III and Phase II are identical, but I could be mistaken. Is likelihood of Phase III success 50, 70, or 90% (directionally). Why? Appreciate thoughtful responses. Thank you all. Disclosure: I hold 33k shares.
David987654321, published July 31, 2021

Other Notable StockTweets About VTGN


$VTGN A bullish way to view this primary endpoint for pilot phase 3 is to assume that this crossover study allows for placebo to be no better than 60 SUDs and for Ph94b to be as good as less than 55 SUDs.

Bullish view is that you look at placebo and see where it ended from W 1 and 2.
Then you look at placebo and where it ended from W 3-4. Almost identical.

Another bullish way to look at this is that the Ph94b group that got it first felt this drug working quick.

Placebo group may have been questioning if they received it at the beginning, but that placebo effect was still there from W1-2.

The Ph94b group that got the drug at the beginning clearly felt this drug working, and then they switched over to placebo and knew this wasn’t the drug anymore.

Let’s say you are in this trial and received Ph94b first. On that week 3 crossover you may have more confidence going into the placebo week 3 and deliver a decent speech. But, then W4 comes and now your questioning if you received it.

C_H, published July 27, 2021

$VTGN New SEC Filing: 8-K Emp Changes - VistaGen Therapeutics, Inc. (0001411685) July 21


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Resignation of Dr. Brian J. Underdown and Appointment of Ms. Maggie FitzPatrick On July 21, 2021, Dr. Brian J. Underdown notified the Board of Directors (the “Board”) of VistaGen Therapeutics, Inc. (the “Company”) of his retirement from the Board and all Board committees, effective immediately. Dr. Underdown’s decision to retire was not a result of any disagreement with the Company’s management or the Board. Following Dr. Underdown’s resignation and retirement, the Board appointed Margaret M. FitzPatrick to serve on the Board. Ms. FitzPat (...)

https://mkn.re/75344

MarketNewswire, published July 22, 2021

$VTGN Lol fast money momentum trading is a tough way to make a living. But this 15% fade presents a great chance for LT investors to double their money ahead of data readouts next year. And can easily be a 10-bagger if the data is good. I'm a buyer...glta longs!

StankyPigano, published July 13, 2021

$VTGN either this Will go back down to around 2.8 before going back up, or it Will rebounce after the dip it had since 3.6. anyway, its still one of the best stocks with real potensial

hypno123, published July 6, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6297 seconds.